» Articles » PMID: 8769507

Prevalence of Allergic Bronchopulmonary Aspergillosis and Atopy in Adult Patients with Cystic Fibrosis

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 1996 Jun 1
PMID 8769507
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Underestimation of allergic bronchopulmonary aspergillosis (ABPA) prevalence in the cystic fibrosis (CF) population is suspected due to nonuniform diagnostic criteria, nonspecific signs and symptoms, assessment during asymptomatic intervals, and physician nonaggressiveness in making the diagnosis.

Objective: To define the prevalence of ABPA in adult patients with CF, as the increased duration of bronchiectasis may increase the probability of Aspergillus fumigatus (Af) colonization. We also sought to determine whether atopy increases the prevalence of ABPA in adults with CF.

Methods: We examined a cross-sectional population of adult patients with CF at the University of Washington for 1 year.

Results: Information was collected on 53 of 65 (82%) patients. Fifteen of 51 (29%) had an immediate skin test reaction to Af, and 30 of 51 (59%) had at least one positive skin test. Increased total serum IgE (>450 IU/mL) was present in 0 of 53; increased IgE-Af and IgG-Af were found in 12 of 53 (23%) and 9 of 53 (17%), respectively; 24 of 53 (45%) had Af-precipitins. Peripheral blood eosinophilia was present in one patient. Eight of 49 (16%) patients' sputum cultures grew Af. ABPA-CB (ABPA-central bronchiectasis) was present in one patient and ABPA-S (ABPA-seropositive) in no patients. Atopy was present in 20 of 51 (39%).

Conclusion: There was a low prevalence of ABPA in the adult CF population despite frequent immunologic responses to Af. The prevalence of ABPA was too small to determine an association with atopy.

Citing Articles

Clinical Impact of in Children with Cystic Fibrosis.

Fainardi V, Sodini C, Deolmi M, Ciuni A, Skenderaj K, Stabile M Microorganisms. 2022; 10(4).

PMID: 35456789 PMC: 9032721. DOI: 10.3390/microorganisms10040739.


Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Jat K, Walia D, Khairwa A Cochrane Database Syst Rev. 2021; 9:CD010288.

PMID: 34550603 PMC: 8457344. DOI: 10.1002/14651858.CD010288.pub5.


Coinfection with and in cystic fibrosis.

Keown K, Reid A, Moore J, Taggart C, Downey D Eur Respir Rev. 2020; 29(158).

PMID: 33208485 PMC: 9489137. DOI: 10.1183/16000617.0011-2020.


Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.

Sunman B, Tural D, Ozsezen B, Emiralioglu N, Yalcin E, Ozcelik U Front Pediatr. 2020; 8:582964.

PMID: 33194914 PMC: 7606581. DOI: 10.3389/fped.2020.582964.


Interaction between and in cystic fibrosis.

Zhao J, Yu W PeerJ. 2018; 6:e5931.

PMID: 30430043 PMC: 6231424. DOI: 10.7717/peerj.5931.